InsidersTradesSigma
Contineum Therapeutics, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)
Follow the Contineum Therapeutics, Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Contineum Therapeutics, Inc. has logged 22 insider filings. Market capitalisation: €577.6m. The latest transaction was reported on 8 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Lorrain Daniel S.. The full history is free.
22
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€397,543
11 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Contineum Therapeutics, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$22.33.
38Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 8 July 2026
Declarations22 total
2,500 shares@ US$14.56CommonSEC144:0001950047-26-006968
2,500 shares@ US$1.010.0005% mcap4.7% of flowClass A Common StockSEC:0001628280-26-047710:0
2,500 shares@ US$16.000.0074% mcap75.1% of flowClass A Common StockSEC:0001628280-26-047710:1
7,500 sharesClass A Common StockSEC:0001628280-26-046653:0
2,500 sharesClass A Common StockSEC:0001628280-26-046653:1
10,000 sharesClass A Common StockSEC:0001628280-26-046653:2
10,833 sharesClass A Common StockSEC:0001628280-26-046654:0
10,833 sharesClass A Common StockSEC:0001628280-26-046654:1
4,170 shares@ US$13.15640.011% mcap8.2% of flowClass A Common StockSEC:0001628280-26-039641:0
3,870 shares@ US$13.060.010% mcap10.3% of flowClass A Common StockSEC:0001628280-26-029435:0
4,170 shares@ US$13.43260.011% mcap11.6% of flowClass A Common StockSEC:0001628280-26-023949:0
4,400 shares@ US$1.260.0011% mcap50.0% of flowClass A Common StockSEC:0001437749-26-005892:0
4,300 shares@ US$1.010.0009% mcap0.9% of flowClass A Common StockSEC:0001437749-26-005889:0
3,000 shares@ US$14.82290.0088% mcap9.0% of flowClass A Common StockSEC:0001437749-26-003212:0
3,611 shares@ US$4.500.0032% mcap24.7% of flowClass A Common StockSEC:0001437749-26-002575:0
3,670 shares@ US$10.34830.0076% mcap7.8% of flowClass A Common StockSEC:0001437749-26-000616:0
4,170 shares@ US$12.23240.010% mcap10.4% of flowClass A Common StockSEC:0001437749-25-038936:0
3,611 shares@ US$4.500.0032% mcap25.3% of flowClass A Common StockSEC:0001437749-25-038938:0
1,010 shares@ US$16.01722.7% of flowClass A Common StockSEC:0001437749-24-036349:0
6,091 shares@ US$16.373816.5% of flowClass A Common StockSEC:0001437749-24-035887:0
12,800 shares@ US$1.01100.0% of flowClass A Common StockSEC:0001437749-24-026903:0
391,785 sharesClass A Common StockSEC:0000899243-24-000269:0
22 of 22 declarations
About Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc. (ticker: CTNM) is a U.S.-listed biopharmaceutical company traded on NASDAQ in the United States, and it is best viewed as a clinical-stage biotech rather than a commercial-stage drug maker. The company is headquartered in San Diego, California, and was incorporated in Delaware in 2009. In November 2023, it changed its name from Pipeline Therapeutics, Inc. to Contineum Therapeutics, Inc. to reflect a broader focus on neuroscience, inflammation, and immunology, or NI&I. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1855175/000162828026030614/ctnm-20260331.htm?utm_source=openai)) Contineum’s core business is the discovery and development of novel oral small-molecule therapeutics aimed at diseases with significant unmet medical need. The company’s model is centered on internal R&D and clinical advancement, not on generating revenue from marketed products. Its lead asset is PIPE-791, a brain-penetrant LPA1 receptor antagonist being developed for idiopathic pulmonary fibrosis (IPF). Another key program is PIPE-307, a selective muscarinic M1 receptor antagonist being advanced in neurological indications. Contineum has also nominated CTX-343, a peripherally restricted LPA1R antagonist, underscoring that the company is building a multi-asset discovery platform around related biology. ([contineum-tx.com](https://contineum-tx.com/pipeline/?utm_source=openai)) From a competitive standpoint, Contineum occupies a specialized niche within the biotech universe. Its investment case is built on scientific differentiation, target validation, and the ability to move programs through the clinic with convincing safety and efficacy data. The portfolio spans two attractive therapeutic themes: fibrosis/respiratory disease through PIPE-791 and central nervous system disease through PIPE-307. A notable strategic feature is the global license and development agreement with Janssen for PIPE-307, which provides external validation and potentially broadens the path to development and future value creation. ([ir.contineum-tx.com](https://ir.contineum-tx.com/news-releases/news-release-details/pipeline-therapeutics-announces-global-license-and-development/?utm_source=openai)) Recent company highlights have centered on clinical execution and milestone delivery. Throughout 2025, Contineum reported financial and operational updates showing higher R&D spending, largely driven by advancement of PIPE-791 and PIPE-307, while also pointing to upcoming topline clinical readouts. For equity investors, CTNM should therefore be seen as a high-risk, high-upside clinical biotech with a clearly defined pipeline, meaningful scientific ambition, and significant dependence on trial outcomes and partnership execution. ([ir.contineum-tx.com](https://ir.contineum-tx.com/news-releases/news-release-details/contineum-therapeutics-reports-second-quarter-2025-financial/?utm_source=openai))
